SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2016
Commission File Number: 001-37710
HUTCHISON CHINA MEDITECH LIMITED
(Translation of registrant’s name into English)
22/F, Hutchison House, 10 Harcourt Road, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
HUTCHISON CHINA MEDITECH LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
|
Description |
|
|
|
Exhibit 99.1 |
Announcement relating to total voting rights |
|
Exhibit 99.2 |
Announcement relating to exercise of share options by a person discharging managerial responsibilities |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
HUTCHISON CHINA MEDITECH LIMITED |
||
|
|
|
|
|
|
|
|
|
By: |
/s/ Johnny Cheng |
|
|
Name: |
Johnny Cheng |
|
|
Title: |
Chief Financial Officer |
Date: November 30, 2016
3
Exhibit 99.1
Total Voting Rights
London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 60,703,323 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 60,703,323 ordinary shares would be equivalent to 60,703,323 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 121,406,646 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries |
|
|
Christian Hogg, CEO |
+852 2121 8200 |
|
|
|
|
International Media Enquiries |
|
|
Anthony Carlisle, |
+44 7973 611 888 (Mobile) |
anthony.carlisle@cdrconsultancy.co.uk |
|
|
|
U.S. Based Media Enquiries |
|
|
Brad Miles, BMC Communications |
+1 (917) 570 7340 (Mobile) |
bmiles@bmccommunications.com |
|
|
|
Susan Duffy, BMC Communications |
+1 (917) 499 8887 (Mobile) |
sduffy@bmccommunications.com |
|
|
|
Investor Relations |
|
|
Matt Beck, The Trout Group |
+1 (917) 415 1750 (Mobile) |
mbeck@troutgroup.com |
|
|
|
David Dible, Citigate Dewe Rogerson |
+44 7967 566 919 (Mobile) |
david.dible@citigatedr.co.uk |
|
|
|
Panmure Gordon (UK) Limited |
|
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
|
Exhibit 99.2
Exercise of Share Options by a Person Discharging Managerial Responsibilities
London: Wednesday, November 30, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Responsibilities), has exercised 25,535 share options (granted in 2007 and which are soon due to expire in May 2017) over ordinary shares of US$1.00 each in Chi-Med (the “Ordinary Shares”) at an exercise price of GBP1.535 per share on November 25, 2016. Such Ordinary Shares will be held in the form of American Depositary Shares (“ADSs”) each representing one half of one Ordinary Share.
Following the above exercise of options and subject to the completion of allotment, the holding of Dr Su is 25,535 Ordinary Shares, representing approximately 0.04% of the current issued share capital of Chi-Med, which he intends to hold as a long term investment. Additionally Dr Su holds a further 300,000 unexercised options which would represent a further 0.49% of the issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
|
|
|
a) |
Name |
Dr Weiguo Su |
|
2 |
Reason for the notification |
||
|
|
|
|
a) |
Position/status |
Executive Vice President and Chief Scientific Officer of Chi-Med |
|
|
|
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
|
|
|
a) |
Name |
Hutchison China MediTech Limited |
|
|
|
|
|
b) |
LEI |
N/A |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
|
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of US$1.00 each in the form of ADSs each representing one half of one Ordinary Share of US$1.00
|
|
|
Identification code |
DI ISIN: KYG4672N1016 |
|
|
|
|
|
|
|
ADS ISIN: US44842L1035 |
|
|
|
|
|
b) |
Nature of the transaction |
Exercise of share options on November 25, 2016 at a price of GBP1.535 per share. Such Ordinary Shares will be held in the form of ADSs. |
|
|
|
|
|
|
|
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
GBP1.535 |
25,535 |
|
|
|
|
|
|
|
|
d) |
Aggregated information |
Aggregated volume: 25,535 |
|
|
— Aggregated volume |
Price information: GBP1.535 |
|
|
— Price |
|
|
|
|
|
|
e) |
Date of the transaction |
2016-11-25 |
|
|
|
|
|
|
|
|
|
f) |
Place of the transaction |
Outside a trading venue
|
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries Christian Hogg, CEO |
+852 2121 8200 |
|
|
|
|
International Media Enquiries |
|
|
Anthony Carlisle, Citigate Dewe Rogerson |
+44 7973 611 888 (Mobile) |
anthony.carlisle@cdrconsultancy.co.uk |
|
|
|
U.S. Based Media Enquiries |
|
|
Brad Miles, BMC Communications |
+1 (917) 570 7340 (Mobile) |
bmiles@bmccommunications.com |
Susan Duffy, BMC Communications |
+1 (917) 499 8887 (Mobile) |
sduffy@bmccommunications.com |
|
|
|
Investor Relations |
|
|
Matt Beck, The Trout Group |
+1 (917) 415 1750 (Mobile) |
mbeck@troutgroup.com |
David Dible, Citigate Dewe Rogerson |
+44 7967 566 919 (Mobile) |
david.dible@citigatedr.co.uk |
|
|
|
Panmure Gordon (UK) Limited |
|
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
|